



**XI<sup>th</sup> International  
Myeloma Workshop**  
& **IV<sup>th</sup> International Workshop  
on Waldenström's  
Macroglobulinemia**

*Kos Island, Greece, 25-30 June 2007*

**Organized by:**

*Department of Clinical Therapeutics*

*Alexandra Hospital*

*Medical School*

*National & Kapodistrian University of Athens*

***IV<sup>th</sup> International  
Workshop on Waldenström's  
Macroglobulinemia***

*Scientific Programme*



*IVth International Workshop on  
Waldenström's Macroglobulinemia  
Scientific Programme*

*Friday, June 29, 2007*

*Hall Hippocrates*

<b>14:00-14:30</b>		<b>Opening Addresses - Kyle Award</b>
<b>14:30-16:50</b>	<b>WM1</b>	<b>Genetics, Pathophysiology and Staging System</b> Chair: <b>M.A. Dimopoulos, Greece - S. Treon, USA</b>
14:30-14:50	WM1.1	<b>G.A. Pangalis, Greece:</b> Biologic and clinical overlap of IgM-Secreting lymphomas; Focus on Waldenström's Macroglobulinemia (WM)
14:50-15:10	WM1.2	<b>S.S. Sahota, United Kingdom:</b> Tracking the malignant cell of origin in Waldenström's Macroglobulinemia
15:10-15:30	WM1.3	<b>R. Garcia-Sanz, Spain:</b> Immunoglobulin gene rearrangements in WM
15:30-15:50	WM1.4	<b>L.M. Pilarski, Canada:</b> Inherited and acquired mutations in Waldenström's Macroglobulinemia (WM): WM and MM have a close genetic relationship not shared with B-CLL
15:50-16:10	WM1.5	<b>R. Fonseca, USA:</b> Genetics and Genomics of Waldenström Macroglobulinemia
16:10-16:30	WM1.6	<b>E. Morra, Italy:</b> IgM MGUS and Asymptomatic WM: Prognostic factors and evolution
16:30-16:50	WM1.7	<b>P. Morel, France:</b> International prognostic scoring system for Waldenström's Macroglobulinemia
<b>17:00-18:00</b>		<b>Poster Session III</b>

*Saturday, June 30, 2007**Hall Hippocrates*

08:00-10:00	WM2	<b>Frontline treatment of WM</b> Chair: <b>M. Gertz, USA</b>
08:00-08:20	WM2.1	<b>R.A. Kyle, USA:</b> Indications for treatment and the role of Alkylating agents in WM
08:20-08:40	WM2.2	<b>V. LeBlond, France:</b> Role of purine analogs in front-line treatment of Waldenström's Macroglobulinemia
08:40-09:00	WM2.3	<b>D.M. Weber, USA:</b> Rituximab alone or in combination in the frontline treatment of WM
09:00-09:20	WM2.4	<b>M.A. Gertz, USA:</b> Overview in salvage treatment in WM
09:20-09:40	WM2.5	<b>A. Anagnostopoulos, Greece:</b> The role of autologous transplantation in WM
09:40-10:00	WM2.6	<b>S.P. Treon, USA:</b> Novel agents in the treatment of Waldenström's Macroglobulinemia: Update of WMCTG Clinical Trials
10:00-10:30		Coffee Break

*Hall Hippocrates*

10:30-13:20	WM3	<b>Novel treatment approaches, treatment of advanced disease</b> Chair: <b>V. LeBlond, France - A. Anagnostopoulos, Greece</b>
10:30-10:50	WM3.1	<b>I. Ghobrial, USA:</b> Proteomic analysis in WM
10:50-11:05	WM3.2	<b>N.C. Gutierrez, Spain:</b> The gene expression signature of clonal cells from Waldenström's Macroglobulinemia: differences and commonalities with the normal cell counterpart and other related lymphoproliferative disorders
11:05-11:20	WM3.3	<b>E. Hatjiharissi, USA:</b> Gene expression profiling of Waldenström's Macroglobulinemia reveals genes that may be related to disease pathogenesis

Saturday, June 30, 2007 ■

*Hall Hippocrates*

- |             |        |  |
|-------------|--------|--|
| 11:20-11:35 | WM3.4  | <b>E. Hatjiharissi, USA:</b> Novel splice variant transcript of Siva in Waldenström's Macroglobulinemia  |
| 11:35-11:50 | WM3.5  | <b>S. Adamia, USA:</b> Aberrant post-transcriptional regulation of TNF family members and their adaptor molecules essential to B-cell growth and survival in Waldenström's Macroglobulinemia                     |
| 11:50-12:05 | WM3.6  | <b>B.T. Ciccarelli, USA:</b> The functional role of CD27-CD70 interactions in Waldenström's Macroglobulinemia  |
| 12:05-12:20 | WM3.7  | <b>A. Anagnostopoulos, Greece:</b> Serum concentrations of angiogenic cytokines in Waldenström's Macroglobulinemia: The ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity |
| 12:20-12:35 | WM3.8  | <b>J. Soumerai, USA:</b> Use of the immunomodulators thalidomide and lenalidomide to augment rituximab clinical activity in Waldenström's Macroglobulinemia  |
| 12:35-12:50 | WM3.9  | <b>C. Kyriakou, United Kingdom:</b> Allogeneic stem cell transplantation (ALLO-SCT) in Waldenström's Macroglobulinemia (WM). An analysis of 106 cases from the european bone marrow registry (EBMT)              |
| 12:50-13:05 | WM3.10 | <b>X. Leleu, USA:</b> Increased incidence of disease transformation and development of MDS/AML in Waldenström's Macroglobulinemia (WM) patients treated with nucleoside analogues.                               |
| 13:05-13:20 | WM3.11 | <b>A.D. Wechalekar, United Kingdom:</b> Clinical Profile And Treatment Outcome In 103 Patients With AL Amyloidosis Associated With IgM Paraproteinemia   |
| 13:20-14:30 |        | Lunch Break  |

*Hall Hippocrates*

14:30-16:30

**Consensus on WM treatment**

Chair: **S.P. Treon, USA** - **M.A. Dimopoulos, Greece**